TIL Quote, Financials, Valuation and Earnings

Merck & has a net margin of -- compared to Instil Bio's net margin of 32.71%. Instil Bio's return on equity of -- beat Merck &'s return on equity of 39.02%.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 216.4%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 24.4%. Given that Instil Bio has higher upside potential than Merck &, analysts believe Instil Bio is more attractive than Merck &.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.86% to investors and pays a quarterly dividend of $0.81 per share. Instil Bio pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Instil Bio quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Instil Bio's net income of -$28.2M is lower than Merck &'s net income of $5.1B. Notably, Instil Bio's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 3.25x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Instil Bio's net margin of -907.48%. Instil Bio's return on equity of -- beat Moderna's return on equity of -29.23%.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 216.4%. On the other hand Moderna has an analysts' consensus of $47.64 which suggests that it could grow by 74.17%. Given that Instil Bio has higher upside potential than Moderna, analysts believe Instil Bio is more attractive than Moderna.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Moderna quarterly revenues of $107M. Instil Bio's net income of -$28.2M is higher than Moderna's net income of -$971M. Notably, Instil Bio's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 3.39x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Instil Bio's net margin of 26.7%. Instil Bio's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 216.4%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 39.36%. Given that Instil Bio has higher upside potential than Regeneron Pharmaceuticals, analysts believe Instil Bio is more attractive than Regeneron Pharmaceuticals.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.34% to investors and pays a quarterly dividend of $0.88 per share. Instil Bio pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Instil Bio's net income of -$28.2M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Instil Bio's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus 4.23x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vera Therapeutics has a net margin of -- compared to Instil Bio's net margin of --. Instil Bio's return on equity of -- beat Vera Therapeutics's return on equity of --.

Instil Bio has a consensus price target of $118.67, signalling upside risk potential of 216.4%. On the other hand Vera Therapeutics has an analysts' consensus of $64.86 which suggests that it could grow by 188%. Given that Instil Bio has higher upside potential than Vera Therapeutics, analysts believe Instil Bio is more attractive than Vera Therapeutics.

Instil Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vera Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Instil Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vera Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Instil Bio pays -- of its earnings as a dividend. Vera Therapeutics pays out -- of its earnings as a dividend.

Instil Bio quarterly revenues are --, which are smaller than Vera Therapeutics quarterly revenues of --. Instil Bio's net income of -$28.2M is higher than Vera Therapeutics's net income of -$51.7M. Notably, Instil Bio's price-to-earnings ratio is -- while Vera Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Instil Bio is -- versus -- for Vera Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.